vs
Criteo S.A.（CRTO）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是Criteo S.A.的1.3倍（$622.0M vs $482.7M），Royalty Pharma plc净利率更高（34.4% vs 4.4%，领先30.0%），Royalty Pharma plc同比增速更快（4.8% vs 2.4%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs 1.4%）
Criteo S.A.是一家总部位于法国巴黎的广告服务商，专注于为客户提供在线展示广告服务，帮助品牌与媒体触达目标受众，是全球互联网广告领域的知名企业，深耕效果营销领域多年，服务众多跨境与本土客户。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
CRTO vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.3倍
$482.7M
营收增速更快
RPRX
高出2.4%
2.4%
净利率更高
RPRX
高出30.0%
4.4%
两年增速更快
RPRX
近两年复合增速
1.4%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $482.7M | $622.0M |
| 净利润 | $21.3M | $214.2M |
| 毛利率 | 53.6% | — |
| 营业利润率 | 6.3% | 62.4% |
| 净利率 | 4.4% | 34.4% |
| 营收同比 | 2.4% | 4.8% |
| 净利润同比 | -21.3% | 2.9% |
| 每股收益（稀释后） | $0.39 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRTORPRX
| Q4 25 | — | $622.0M | ||
| Q3 25 | — | $609.3M | ||
| Q2 25 | $482.7M | $578.7M | ||
| Q1 25 | $451.4M | $568.2M | ||
| Q4 24 | $553.0M | $593.6M | ||
| Q3 24 | $458.9M | $564.7M | ||
| Q2 24 | $471.3M | $537.3M | ||
| Q1 24 | $450.1M | $568.0M |
净利润CRTORPRX
| Q4 25 | — | $214.2M | ||
| Q3 25 | — | $288.2M | ||
| Q2 25 | $21.3M | $30.2M | ||
| Q1 25 | $37.9M | $238.3M | ||
| Q4 24 | $71.1M | $208.2M | ||
| Q3 24 | $6.2M | $544.0M | ||
| Q2 24 | $27.0M | $102.0M | ||
| Q1 24 | $7.2M | $4.8M |
毛利率CRTORPRX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 53.6% | — | ||
| Q1 25 | 52.5% | — | ||
| Q4 24 | 54.4% | — | ||
| Q3 24 | 50.5% | — | ||
| Q2 24 | 49.4% | — | ||
| Q1 24 | 48.3% | — |
营业利润率CRTORPRX
| Q4 25 | — | 62.4% | ||
| Q3 25 | — | 70.1% | ||
| Q2 25 | 6.3% | 36.3% | ||
| Q1 25 | 10.7% | 94.0% | ||
| Q4 24 | 17.1% | 60.9% | ||
| Q3 24 | 2.1% | — | ||
| Q2 24 | 7.8% | 50.2% | ||
| Q1 24 | 2.3% | -13.0% |
净利率CRTORPRX
| Q4 25 | — | 34.4% | ||
| Q3 25 | — | 47.3% | ||
| Q2 25 | 4.4% | 5.2% | ||
| Q1 25 | 8.4% | 41.9% | ||
| Q4 24 | 12.9% | 35.1% | ||
| Q3 24 | 1.4% | 96.3% | ||
| Q2 24 | 5.7% | 19.0% | ||
| Q1 24 | 1.6% | 0.8% |
每股收益（稀释后）CRTORPRX
| Q4 25 | — | $0.49 | ||
| Q3 25 | — | $0.67 | ||
| Q2 25 | $0.39 | $0.07 | ||
| Q1 25 | $0.66 | $0.55 | ||
| Q4 24 | $1.21 | $0.46 | ||
| Q3 24 | $0.11 | $1.21 | ||
| Q2 24 | $0.46 | $0.23 | ||
| Q1 24 | $0.12 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $223.6M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $1.1B | $9.7B |
| 总资产 | $2.1B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资CRTORPRX
| Q4 25 | — | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | $223.6M | $631.9M | ||
| Q1 25 | $313.2M | $1.1B | ||
| Q4 24 | $316.9M | $929.0M | ||
| Q3 24 | $231.8M | $950.1M | ||
| Q2 24 | $233.2M | $1.8B | ||
| Q1 24 | $278.1M | $843.0M |
总债务CRTORPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益CRTORPRX
| Q4 25 | — | $9.7B | ||
| Q3 25 | — | $9.6B | ||
| Q2 25 | $1.1B | $9.5B | ||
| Q1 25 | $1.1B | $9.8B | ||
| Q4 24 | $1.0B | $10.3B | ||
| Q3 24 | $1.1B | $10.3B | ||
| Q2 24 | $1.0B | $9.8B | ||
| Q1 24 | $1.0B | $9.9B |
总资产CRTORPRX
| Q4 25 | — | $19.6B | ||
| Q3 25 | — | $19.3B | ||
| Q2 25 | $2.1B | $18.3B | ||
| Q1 25 | $2.1B | $17.6B | ||
| Q4 24 | $2.3B | $18.2B | ||
| Q3 24 | $2.2B | $18.0B | ||
| Q2 24 | $2.2B | $17.7B | ||
| Q1 24 | $2.2B | $16.1B |
负债/权益比CRTORPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.4M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $-36.6M | — |
| 自由现金流率自由现金流/营收 | -7.6% | — |
| 资本支出强度资本支出/营收 | 7.3% | — |
| 现金转化率经营现金流/净利润 | -0.07× | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CRTORPRX
| Q4 25 | — | $827.1M | ||
| Q3 25 | — | $702.6M | ||
| Q2 25 | $-1.4M | $364.0M | ||
| Q1 25 | $62.3M | $596.1M | ||
| Q4 24 | $169.5M | $742.5M | ||
| Q3 24 | $57.5M | $703.6M | ||
| Q2 24 | $17.2M | $658.2M | ||
| Q1 24 | $14.0M | $664.6M |
自由现金流CRTORPRX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-36.6M | — | ||
| Q1 25 | $45.3M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-4.0M | — | ||
| Q1 24 | $173.0K | — |
自由现金流率CRTORPRX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -7.6% | — | ||
| Q1 25 | 10.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -0.9% | — | ||
| Q1 24 | 0.0% | — |
资本支出强度CRTORPRX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 7.3% | — | ||
| Q1 25 | 3.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 4.5% | — | ||
| Q1 24 | 3.1% | — |
现金转化率CRTORPRX
| Q4 25 | — | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | -0.07× | 12.06× | ||
| Q1 25 | 1.64× | 2.50× | ||
| Q4 24 | 2.38× | 3.57× | ||
| Q3 24 | 9.21× | 1.29× | ||
| Q2 24 | 0.64× | 6.45× | ||
| Q1 24 | 1.93× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRTO
| Commerce Growth | $393.9M | 82% |
| Retail Media | $60.9M | 13% |
| Other | $27.9M | 6% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
